Verdel B Marianne, Souverein Patrick C, Egberts Antoine Cg, Leufkens Hubert Gm
Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, Netherlands.
Ann Pharmacother. 2006 Jun;40(6):1040-6. doi: 10.1345/aph.1G642. Epub 2006 May 30.
The chemical structure of sulfonamide antibiotics and sulfonamide nonantibiotics can affect the potential for adverse reactions.
To assess whether differences in chemical structure of the various sulfonamide drugs influence the risk of allergic events.
A case-control study was conducted among patients with diabetes mellitus (DM) using data from the General Practice Research Database. Cases were defined as patients with a diagnosis of hypersensitivity or allergic reaction. The date of the last event was the index date. Controls were matched on practice, type of DM, and index date. Current use of sulfonamides was defined as use in a 14 day time window before the index date. Sulfonamides were classified according to the presence/absence of an N1 substituent (N1(+)/(-)) and/or an arylamine (N4(+)/(-)). Conditional logistic regression was used to estimate strength of association and expressed as odds ratios and 95% confidence intervals.
Overall, current use of N1(+) N4(+) sulfonamide drugs was associated with the outcome (adjusted OR 3.71; 95% CI 1.40 to 9.81). Current use of N1(+) N4(-) and N1(-) N4(-) sulfonamide drugs was also associated with the occurrence of allergic reactions, although not as strongly: adjusted OR 2.48 (95% CI 2.12 to 2.89) and 2.07 (95% CI 1.74 to 2.46), respectively. Sex and age seemed to be effect modifiers. There was no clear evidence for effect modification by immune disease state.
Although we did not identify major differences between the groups, we believe that this approach is an innovative manner to examine adverse drug reactions by using chemical structure instead of therapeutic drug classes to classify exposure.
磺胺类抗生素和非抗生素类磺胺的化学结构可能影响不良反应的发生可能性。
评估各类磺胺药物化学结构的差异是否会影响过敏事件的风险。
利用全科医学研究数据库的数据,对糖尿病患者开展病例对照研究。病例定义为诊断为超敏反应或过敏反应的患者。最后一次事件发生日期为索引日期。对照组在医疗机构、糖尿病类型和索引日期方面进行匹配。当前使用磺胺类药物定义为在索引日期前14天内使用。磺胺类药物根据是否存在N1取代基(N1(+)/(-))和/或芳胺(N4(+)/(-))进行分类。采用条件逻辑回归估计关联强度,以比值比和95%置信区间表示。
总体而言,当前使用N1(+) N4(+)磺胺类药物与研究结果相关(调整后的比值比为3.71;95%置信区间为1.40至9.81)。当前使用N1(+) N4(-)和N1(-) N4(-)磺胺类药物也与过敏反应的发生相关,尽管相关性没那么强:调整后的比值比分别为2.48(95%置信区间为2.12至2.89)和2.07(95%置信区间为1.74至2.46)。性别和年龄似乎是效应修饰因素。没有明确证据表明免疫疾病状态会产生效应修饰作用。
尽管我们未发现各组之间存在重大差异,但我们认为这种方法是一种创新方式,通过使用化学结构而非治疗药物类别对暴露进行分类来研究药物不良反应。